Bioventus (NASDAQ:BVS) Hits New 1-Year High – What’s Next?

Bioventus Inc. (NASDAQ:BVS) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $9.69 and last traded at $9.6480, with a volume of 20136 shares. The stock had previously closed at $9.42.

Analysts Set New Price Targets

A number of brokerages have recently commented on BVS. Barrington Research increased their price objective on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Craig Hallum upped their target price on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. CJS Securities assumed coverage on Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. Finally, Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Bioventus has a consensus rating of “Buy” and a consensus target price of $14.00.

Bioventus Price Performance

The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 1.22. The stock has a fifty day simple moving average of $8.74 and a 200-day simple moving average of $7.83. The stock has a market cap of $807.39 million, a price-to-earnings ratio of 29.39 and a beta of 0.70.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The company had revenue of $157.90 million during the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Insider Buying and Selling

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares of the company’s stock, valued at $395,523.63. This represents a 21.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP grew its position in Bioventus by 0.4% during the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after buying an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after acquiring an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after acquiring an additional 1,887 shares during the period. Deutsche Bank AG grew its holdings in shares of Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares in the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.